Navigation Links
PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
Date:6/17/2008

contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 a
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
2. PAREXEL Reaches Agreement To Acquire ClinPhone
3. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
4. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
5. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
6. PAREXEL Reports Third Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
8. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
9. PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France
10. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 SPIE Fellow ... Physics and Optical Science and Director of the Center ... North Carolina at Charlotte, and co-founder and Chairman of ... serve as the 2015 Vice President of SPIE, the ... President Philip Stahl announced recent election results at the ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides users ... said Mark Tess, PhD, Mycotoxin Product Manager for Charm Sciences. ... USDA-GIPSA inspection agencies that have a need to detect aflatoxin ... a matter of minutes with nothing but our equipment and ... grain before accepting it, but they no longer have to ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:8/31/2014)... and accurate tool to diagnose tuberculosis in children, ... test (TAM-TB assay) is the first reliable immunodiagnostic ... test features excellent specificity, a similar sensitivity as ... blood test. The promising findings are a major ... particularly in tuberculosis-endemic regions. , The study has ...
(Date:8/31/2014)... the greatest challenges in modern medicine is developing drugs ... minimal toxicity and side-effects to the patient. Such properties ... drug molecule. Ideally, the drug should have a shape ... that it binds it with high specificity. Publishing in ... synthetic amino acid that can impact the 3D structure ...
(Date:8/31/2014)... study of satellite data from the last 19 years reveals ... around the coast of Antarctica to rise by 2cm more ... University of Southampton detected the rapid rise in sea-level by ... a million square kilometres. , The melting of ... shelves has contributed an excess of around 350 gigatonnes of ...
Breaking Biology News(10 mins):New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... June 28, 2013 -- A single systemic dose of ... in a preclinical animal model of kidney transplantation, according ... Medicine. Their findings, now available in the online version ... lay the foundation for eventual human trials of the ...
... the ,parrot dinosaur, is known from more than 1000 specimens from ... of east Asia. As part of his PhD thesis at ... the Institute for Vertebrate Paleontology in Beijing, carried out the intricate ... said: "Some of the bones from baby Psittacosaurus were ...
... multitude of microbes colonizing and thriving on flecks of ... flotilla of microbial communities that they have dubbed the ... Environmental Science & Technology , the scientists say ... ocean and raises a host of questions: How will ...
Cached Biology News:Dendritic cell therapy improves kidney transplant survival, Pitt team says 2Exploring dinosaur growth 2Scientists discover thriving colonies of microbes in ocean 'plastisphere' 2
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Goat polyclonal to Centaurin alpha 2**...
Biology Products: